Agilent Technologies Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Agilent Technologies Inc trades at $149.06 (market cap $42.22B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.22. The key difference: Agilent Technologies Inc pays a 0.68% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| A | MSTZ | |
|---|---|---|
Market Cap | $42.22B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.20 | $27.92 |
52-Week Low | $110.24 | $3.88 |
Enterprise Value | $43.77B | — |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.72, up 1.88% with strong analyst support (77.5% buy ratings). The stock shows bullish technical momentum above key support levels, supported by consistent revenue around $6.9B and robust profitability with 19.55% net margins. Recent FDA approvals for diagnostic tests and the Biocare Medical acquisition enhance growth prospects in biopharma markets.
Outlook remains positive with a $154.90 consensus price target offering 4% upside, though high P/E of 30.02 poses valuation risk. Key catalysts include Q2 2026 earnings due August 26 and AI-driven lab expansion, while overbought RSI levels near 92 suggest near-term consolidation potential.
MSTZ trades at $11.09, up 2.5% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights ETF performance unrelated to MSTZ, with no direct company updates found.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Risks include market volatility and unverified financial health. Investors need current earnings reports and analyst coverage to assess opportunities amid the bearish technical setup.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →